HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-Dose Prasugrel vs Clopidogrel-Based Tailored Premedication for Endovascular Treatment of Cerebral Aneurysms.

AbstractBACKGROUND:
Antiplatelet premedication is widely accepted for interventional treatment of cerebral aneurysms to prevent thromboembolism. However, antiplatelet resistance sometimes limits the effectiveness of premedication.
OBJECTIVE:
To compare 2 groups administered low-dose prasugrel (PSG group) or clopidogrel-based tailored antiplatelet (CPG group) in terms of platelet function and procedure-related complications.
METHODS:
A total of 411 patients with 505 unruptured aneurysms who underwent endovascular treatment within the past 17 mo were retrospectively enrolled in this study. The PSG (225 patients with 277 aneurysms) and CPG groups (186 patients with 228 aneurysms) were administered the respective medication prior to endovascular treatment. We measure the response to the antiplatelet medication with a laboratory test. Episodes of periprocedural bleeding and thromboembolism were compared between the 2 groups.
RESULTS:
There were significant differences between the 2 groups in terms of the mean P2Y12 reaction unit values (125.7 in the PSG group vs 251.0 in the CPG group; P < .001) and percentage inhibition (57.8% vs 18.7%, respectively; P < .001). Drug resistance was 29.6% per patient in the CPG group and 2.7% per patient in the PSG group. The PSG group reported 1 thromboembolism and bleeding each; meanwhile, the CPG group reported 7 thromboembolism and 3 bleeding. Compared to clopidogrel administration, prasugrel administration significantly decreased the risk of thromboembolism (weighted hazard ratio, 0.17; 95% confidence interval, 0.03-0.99). However, the risk of bleeding was not significant.
CONCLUSION:
Prasugrel was found to be more effective in reducing periprocedural thromboembolism compared to clopidogrel.
AuthorsWon-Sang Cho, Joongyub Lee, Eun Jin Ha, Kyung Hyun Kim, Jeongjun Lee, Young Dae Cho, Jeong Eun Kim, Moon Hee Han, Hyun-Seung Kang
JournalNeurosurgery (Neurosurgery) Vol. 85 Issue 1 Pg. E52-E59 (07 01 2019) ISSN: 1524-4040 [Electronic] United States
PMID30137613 (Publication Type: Journal Article)
CopyrightCopyright © 2018 by the Congress of Neurological Surgeons.
Chemical References
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Prasugrel Hydrochloride
Topics
  • Aged
  • Clopidogrel (therapeutic use)
  • Endovascular Procedures (adverse effects)
  • Female
  • Humans
  • Intracranial Aneurysm (therapy)
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Postoperative Complications (etiology, prevention & control)
  • Prasugrel Hydrochloride (therapeutic use)
  • Premedication (methods)
  • Retrospective Studies
  • Thromboembolism (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: